← ANALYST RATINGS · TIPRANKS
Edwards Lifesciences (EW): analyst forecast and price target
Analyst consensus
Moderate Buy7 Buy3 Hold0 Sell
Ratings of 10 analysts in the last 3 months · top analysts only12-month forecast
Based on 10 price targets given in the last 3 months, the average target is $101, the highest $110, the lowest $85.00. The average is +16.2% from the last price of $86.60.
Analyst ratings 31
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Mike Kratky★★★★★★★★★★#1691 · hits 46% · avg +12.9% | Leerink Partners | $100 → $101+1.0% | Buy | +16.6% | Reiterated | 15.10.26on TipRanks 07:55 | +1.6%next day −0.6% | ↗ |
| Marie Thibault★★★★★★★★★★#12343 · hits 40% · avg −9.7% | BTIG | $110 | Buy | +27.0% | Reiterated | 09.10.26on TipRanks Oct 12 09:45 | +0.6%next day +1.4% · 5 days +3.6% | ↗ |
| Patrick Wood★★★★★★★★★★#10768 · hits 50% · avg −2.1% | UBS | $110 | Buy | +27.0% | Reiterated | 07.10.26on TipRanks Oct 8 06:15 | −0.6%next day −1.4% · 5 days +1.8% | ↗ |
| Matt Miksic★★★★★★★★★★#2645 · hits 55% · avg +3.9% | Barclays | $110 | Buy | +27.0% | Initiated | 07.10.26on TipRanks 03:55 | −0.6%next day −1.4% · 5 days +1.8% | ↗ |
| Joanne Wuensch★★★★★★★★★★#3684 · hits 55% · avg +2.3% | Citi | $110 | Buy | +27.0% | Reiterated | 05.10.26on TipRanks 07:16 | +1.8%next day −1.4% · 5 days −1.4% | ↗ |
| Name not given | — | $110 | Buy | +27.0% | Reiterated | 01.10.26on TipRanks Oct 2 21:45 | −1.5%next day −0.8% · 5 days −2.4% | ↗ |
| Mike Kratky★★★★★★★★★★#1691 · hits 46% · avg +12.9% | Leerink Partners | $101 | Buy | +16.6% | Reiterated | 28.09.26on TipRanks Sep 29 01:15 | +1.4%next day +1.6% · 5 days −0.7% | ↗ |
| Adam Maeder★★★★★★★★★★#1026 · hits 54% · avg +11.3% | Piper Sandler | $101 | Buy | +16.6% | Reiterated | 21.09.26on TipRanks 06:55 | −1.5%next day +0.5% · 5 days −0.7% | ↗ |
| Matthew Taylor★★★★★★★★★★#1367 · hits 55% · avg +7.2% | Jefferies | $105 | Buy | +21.2% | Reiterated | 11.09.26on TipRanks 10:26 | −3.6%next day +1.8% · 5 days +4.7% | ↗ |
| Marie Thibault★★★★★★★★★★#12343 · hits 40% · avg −9.7% | BTIG | $110 | Buy | +27.0% | Reiterated | 10.09.26on TipRanks Sep 11 05:55 | +1.3%next day −3.6% · 5 days +1.1% | ↗ |
| Brandon Vazquez★★★★★★★★★★#11688 · hits 42% · avg −5.1% | William Blair | — | Buy | — | Reiterated | 10.09.26on TipRanks 18:25 | −3.6%next day +1.8% · 5 days +4.7% | ↗ |
| Joanne Wuensch★★★★★★★★★★#3684 · hits 55% · avg +2.3% | Citi | $110 | Buy | +27.0% | Reiterated | 10.09.26on TipRanks 06:10 | +1.3%next day −3.6% · 5 days +1.1% | ↗ |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $93.00 → $103+10.8% | Buy | +18.9% | Reiterated | 05.08.26on TipRanks 10:06 | — | |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $93.00 → $103+10.8% | Buy | +18.9% | Reiterated | 05.08.26on TipRanks 10:06 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $87.00 → $96.00+10.3% | Hold | +10.9% | Reiterated | 05.08.26on TipRanks 10:06 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $91.00 → $101+11.0% | Buy | +16.6% | Upgrade | 05.08.26on TipRanks 10:06 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $92.00 → $100+8.7% | Buy | +15.5% | Upgrade | 05.08.26on TipRanks 10:06 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $93.00 → $103+10.8% | Buy | +18.9% | Reiterated | 05.08.26on TipRanks 10:06 | — | |
| William Plovanic★★★★★★★★★★#5377 · hits 43% · avg +1.3% | Canaccord Genuity | $85.00 | Hold | −1.8% | Reiterated | 03.08.26on TipRanks Aug 4 07:51 | +1.8%next day −0.9% · 5 days +1.6% | ↗ |
| Robbie Marcus★★★★★★★★★★#1974 · hits 51% · avg +6.5% | J.P. Morgan | $105 | Buy | +21.2% | Reiterated | 28.07.26on TipRanks Jul 29 08:16 | +0.5%next day +4.0% · 5 days +3.0% | ↗ |
| Patrick Wood★★★★★★★★★★#10768 · hits 50% · avg −2.1% | UBS | $90.00 → $110+22.2% | Buy | +27.0% | Upgrade | 28.07.26on TipRanks 08:22 | +0.5%next day +4.0% · 5 days +3.0% | ↗ |
| Rick Wise★★★★★★★★★★#7800 · hits 51% · avg +0.1% | Stifel Nicolaus | $110 | Buy | +27.0% | Reiterated | 24.07.26on TipRanks 09:52 | −1.5%next day +0.5% · 5 days +3.1% | ↗ |
| Suraj Kalia★★★★★★★★★★#1646 · hits 50% · avg +6.8% | Oppenheimer | — | Hold | — | Reiterated | 24.07.26on TipRanks 08:55 | −1.5%next day +0.5% · 5 days +3.1% | ↗ |
| Richard Newitter★★★★★★★★★★#1772 · hits 48% · avg +6.6% | Truist Financial | $95.00 | Hold | +9.7% | Reiterated | 24.07.26on TipRanks 07:56 | −1.5%next day +0.5% · 5 days +3.1% | ↗ |
| Shagun Singh Chadha★★★★★★★★★★#9557 · hits 48% · avg −0.4% | RBC Capital | $110 | Buy | +27.0% | Reiterated | 23.07.26on TipRanks Jul 24 07:21 | +0.6%next day −1.5% · 5 days +3.2% | ↗ |
| Josh Jennings★★★★★★★★★★#3537 · hits 46% · avg +3.0% | TD Cowen | $104 | Buy | +20.1% | Assigned | 23.07.26on TipRanks Jul 24 05:09 | +0.6%next day −1.5% · 5 days +3.2% | ↗ |
| Travis Steed★★★★★★★★★★#3596 · hits 53% · avg +3.0% | Bank of America Securities | $100 | Buy | +15.5% | Reiterated | 21.07.26on TipRanks Jul 24 05:09 | −1.4%next day −0.1% · 5 days 0.0% | ↗ |
| Anthony Petrone★★★★★★★★★★#1225 · hits 54% · avg +8.5% | Mizuho Securities | $100 → $105+5.0% | Buy | +21.2% | Reiterated | 15.07.26on TipRanks 07:54 | −3.5%next day +1.2% · 5 days −2.3% | ↗ |
| Vijay Kumar★★★★★★★★★★#2375 · hits 54% · avg +4.8% | Evercore ISI | $93.00 → $100+7.5% | Buy | +15.5% | Reiterated | 06.07.26on TipRanks 08:50 | 0.0%next day +0.1% · 5 days −3.3% | ↗ |
| David Roman★★★★★★★★★★#3715 · hits 53% · avg +5.3% | Goldman Sachs | $98.00 | Buy | +13.2% | Reiterated | 15.06.26on TipRanks Jun 16 08:11 | −0.4%next day +3.3% · 5 days +3.3% | ↗ |
| David Toung★★★★★★★★★★#1098 · hits 63% · avg +9.1% | Argus Research | — | Buy | — | Reiterated | 21.05.26on TipRanks May 22 10:45 | +0.1%next day +2.7% · 5 days +2.1% | ↗ |
| Matt Miksic★★★★★★★★★★#2645 · hits 55% · avg +3.9% | Barclays | $104 → $110+5.8% | Buy | +27.0% | Reiterated | 24.04.26on TipRanks Apr 26 21:20 | +4.8%next day −1.0% · 5 days −1.1% | ↗ |
| David Rescott★★★★★★★★★★#3448 · hits 49% · avg +5.1% | Robert W. Baird | $85.00 → $87.00+2.4% | Hold | +0.5% | Reiterated | 24.04.26on TipRanks 06:40 | +4.8%next day −1.0% · 5 days −1.1% | ↗ |
| Michael Polark★★★★★★★★★★#2909 · hits 51% · avg +6.5% | Wolfe Research | $92.00 | Buy | +6.2% | Upgrade | 01.04.26on TipRanks 07:10 | +0.7%next day −0.3% · 5 days −6.4% | ↗ |
| Larry Biegelsen★★★★★★★★★★#2729 · hits 53% · avg +3.8% | Wells Fargo | $96.00 → $100+4.2% | Buy | +15.5% | Reiterated | 11.02.26on TipRanks 07:32 | +3.0%next day −2.1% · 5 days +0.6% | ↗ |
| Lee Hambright★★★★★★★★★★#10167 · hits 49% · avg −1.6% | Bernstein | — | Hold | — | Reiterated | 16.01.26on TipRanks Jan 19 12:00 | −0.1%next day +1.0% · 5 days −0.2% | ↗ |
| Jayson Bedford★★★★★★★★★★#819 · hits 60% · avg +8.6% | Raymond James | $96.00 | Buy | +10.9% | Upgrade | 03.11.25on TipRanks 09:20 | +0.6%next day +2.5% · 5 days +1.5% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Edwards Lifesciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $103 at a price of $86.32 (+19.8%); now: $104 at $86.60 (+20.1%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 20 | 19 | 16 | 10 | 10 | 5 |
| Hold | 3 | 5 | 6 | 7 | 5 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.74 (from $0.72 to $0.77). Last quarter: $0.78.
Sales
Next quarter’s sales estimate — $1.7B (from $1.7B to $1.7B). Last quarter: $1.7B.
Best top-analyst consensus in the sector · Healthcare
About Edwards Lifesciences
- CEO: Bernard J. Zovighian
- Employees: 16,000
- One Edwards Way, Irvine, CA, 92614, US
- www.edwards.com
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Data from the stock’s TipRanks forecast page, read 50 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗